Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

"An Introduction to the Founders Workbench"

Summary

Speakers

Robert E. Bishop

John M. Mutkoski

Related Content

Four Steps to Maximize the Value of AI Innovation in Medtech

The Rapid Rise of AI, in Five Charts

What’s Next for AI? Six Areas to Watch in 2024

Open Licenses: An Overview of Open Licenses for Images, Photos, Videos, and Software

Five Tips For Life Sciences Companies To Protect Their AI Technologies

Compliance With New Bayh-Dole Act Regulations Becomes Critically Important

Federal Circuit Will Not Review PTAB’s Use of the Broadest Reasonable Interpretation Claim Construction Standard in Post-Grant Proceedings

Federal Circuit to Consider Whether Delay in Filing Suit Can Bar Damages or Injunctive Relief in Patent Cases

AlloVir and Kalaris Therapeutics to Merge

The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 186 Lawyers

Range Energy Closes on $23.5 Million in New Financing

Acorai raises $4.5 million in oversubscribed series seed round

Nanobiotix Enters Into Licensing, Co-Development, And Commercialization Agreement With Janssen

The Legal 500 United States 2023 Recognizes Goodwin Lawyers and Practices Nationwide

Concert Pharmaceuticals Acquired by Sun Pharmaceutical For $576 Million and Contingent Value Rights

Entrada Therapeutics to Collaborate With Vertex Pharmaceuticals on EEV-Therapeutics, for $250 Million in Equity and Upfront Payments, Up to $485 Million in Milestone Payments, and Royalties

Climate Tech

Life Sciences

Technology

Private Equity

Strategic Technology Transactions and Licensing